Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Consensus Rating of “Hold” from Analysts

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $24.17.

A number of equities research analysts have recently weighed in on DCPH shares. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 29th. Jefferies Financial Group reiterated a “hold” rating and set a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Jonestrading restated a “hold” rating and set a $25.60 price objective on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. JMP Securities reissued a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th.

Deciphera Pharmaceuticals Stock Performance

Shares of DCPH stock opened at $25.59 on Friday. The firm has a fifty day simple moving average of $25.55 and a 200-day simple moving average of $19.45. The company has a market capitalization of $2.21 billion, a PE ratio of -11.58 and a beta of 0.19. Deciphera Pharmaceuticals has a twelve month low of $9.90 and a twelve month high of $25.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Friday, May 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. The company had revenue of $45.00 million during the quarter, compared to analysts’ expectations of $45.99 million. Deciphera Pharmaceuticals had a negative return on equity of 52.42% and a negative net margin of 108.86%. Equities research analysts predict that Deciphera Pharmaceuticals will post -2.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Redmile Group LLC lifted its stake in Deciphera Pharmaceuticals by 10.3% during the first quarter. Redmile Group LLC now owns 5,296,643 shares of the company’s stock valued at $83,316,000 after purchasing an additional 495,103 shares during the last quarter. Armistice Capital LLC lifted its position in shares of Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $83,876,000 after acquiring an additional 588,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Deciphera Pharmaceuticals by 3.7% during the 1st quarter. Vanguard Group Inc. now owns 4,565,044 shares of the company’s stock worth $71,808,000 after acquiring an additional 163,408 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 14.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock worth $37,220,000 after acquiring an additional 290,968 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Deciphera Pharmaceuticals by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock worth $25,191,000 after purchasing an additional 92,410 shares during the period. Institutional investors and hedge funds own 70.96% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.